Strategies to Decrease Taxanes Toxicities in the Adjuvant Treatment of Early Breast Cancer

REFERENCES

• Ferguson T., Wilcken N., Vagg R., et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD004421. DOI: 10.1002/14651858.CD004421.pub2
   PubMed Web of Science ®Google Scholar
• De Laurentiis M., Giuseppe C., D'Agostino D., et al. Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials. J Clin Oncol 2008; 1(26)44–52
   Google Scholar
• Hortobagyi G. N., Holmes F. A. Single-agent Paclitaxel for the treatment of breast cancer: an overview. Semin Oncol 1996; 23(Suppl 1)4–9
   PubMed Web of Science ®Google Scholar
• Trudeau M. E., Eisenhauer E. A., Higgins B. P., et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996; 14: 422–428
   PubMed Web of Science ®Google Scholar
• Seidman A. D. Single-agent Paclitaxel in the treatment of breast cancer: phase I and II development. Semin Oncol Jun, 1999; 26(3 Suppl 8)14–20
   PubMed Web of Science ®Google Scholar
• Culine S. Taxotere as second-line for metastatic breast cancer. Rev Med Interne Mar, 1999; 20(3)277–280
   PubMed Web of Science ®Google Scholar
• Seidman A. D., Berry D., Cirrincione C., et al. CALGB 9840: Phase III. Study of weekly (W) Paclitaxel (P) via 1-hour (H) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol 2004; 22(14S)512
   Google Scholar
• Tabernero J., Climent M. A., Lluch A., et al. A multicentre, randomized phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Annals Oncol 2004; 15(9)1358–1365
   PubMed Web of Science ®Google Scholar
• Cassier P. A., Chabaud S., Trillet-Lenoir V., et al. A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer : results of the ERASME 3 study. Breast Cancer Res Treat Jul 5, 2007, [Epub ahead of print]
   PubMedGoogle Scholar
• Kaufman P. A. Paclitaxel and anthracycline combination chemotherapy for metastatic breast cancer. Semin Oncol Jun, 1999; 26(3 Suppl 8)39–46
   PubMed Web of Science ®Google Scholar
• Nabholtz J. M., Tonkin K., Smylie M., et al. Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: from metastatic to adjuvant setting. Semin Oncol Feb, 1999; 26(1 Suppl 3)10–6
   PubMed Web of Science ®Google Scholar
• Henderson I. C., Berry D. A., Demetri G. D., et al. Improved outcomes from adding sequential paclixaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 976–983
   PubMed Web of Science ®Google Scholar
• Martin M., Pienkowski T., Mackey J., et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352: 2303–2313
   Google Scholar
• Trudeau M., Pagani O. Epirubicin in combination with the taxanes. Semin Oncol Aug, 2001; 28(4 Suppl 12)41–50
   PubMed Web of Science ®Google Scholar
• Airoldi M., Cattel L., Pedani F., et al. Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer. Breast Cancer Res Treat Dec, 2001; 70(3)185–95
   PubMed Web of Science ®Google Scholar
• Salminen E., Syvanen K., Korpela J., et al. Docetaxel with epirubicin-investigations on cardiac safety. Anticancer Drugs Jan, 2003; 14(1)73–77
   PubMed Web of Science ®Google Scholar
• Rischin D., Smith J., Millward M., et al. A phase II trail of Paclitaxel and epirubicin in advanced breast cancer. Br J Cancer 2000; 83: 438–442
   PubMed Web of Science ®Google Scholar
• Bonneterre J., Tubiana-Hulin M., Catimel G. Paclitaxel, epirubicin and Cyclophosphamide Combination in First-line treatment on metastatic breast cancer: A dose escalation study. Oncology 2004; 66: 185–191
   PubMed Web of Science ®Google Scholar
• Conte P. F., Baldini E., Gennari A. Dose-finding study and pharmacokinetics of epirubicin and Paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clinl Oncol 1997; 15: 2510–2517
   PubMed Web of Science ®Google Scholar
• Luck H. J., Thomassen C., Du Bois A., et al. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer. Semin Oncol Oct, 1997; 24(5 Suppl 17)S17–35–S17-39
   Web of Science ®Google Scholar
• Roche H., Fumoleau P., Spielmann M., et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patient: The FNCLCC PACS 01 Trial. J Clin Oncol 2006; 24: 5664–5671
   PubMed Web of Science ®Google Scholar
• Hudis C., Citron M., Berry D., et al. Five year follow-up if INT C9741: Dose-dense chemotherapy is safe and effective. Breast Cancer Res Treat 2005; 94: 39, (Supple; abstr 41)
   Google Scholar
• Moebus V. J., Lueck H. J., Thomssen C., et al. Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) in comparison to conventional schedule chemotherapy in high-risk breast cancer patients (≥ 4+ LN). Mature results of an AGO-trial. Breast Cancer Res Treat 2006; 100(suppl1)S20, Abstract 43
   Google Scholar
• Burnell M., Levine M., Chapman J. A., et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA. 21: results of an interim analysis. Breast Cancer Res Treat 2006; 100(suppl1), Abstract 53
   Google Scholar
• Slamon D. J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Eng J Med Mar 15, 2001; 344(11)783–792
   PubMed Web of Science ®Google Scholar
• Gianni L., Salvatorelli E., Minotti G. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. Cardiovasc Toxicol 2007; 7(2)67–71
   PubMed Web of Science ®Google Scholar
• Ewer M. S., O'Shaughnessy J. A. Cardiac toxicity of trastuzumab-related regimens in HER2 overexpressing breast cancer. Clin Breast Cancer Jun, 2007; 7(8)600–607
   PubMed Web of Science ®Google Scholar
• Slamon D., Eiermann W., Robert N., et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Proceedings of the 29th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, 2006, Abstract 52
   Google Scholar
• Sparano J. A., Wang M., Martino S., et al. Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer. N Engl J Med April, 2008; 358(16)1663–1671
   PubMed Web of Science ®Google Scholar
• Eiermann W., Pienkowski T., Crown J., et al. Phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC-T) in Her-2/neu negative early breast cancer patients with positive axillary lymph nodes: Interim analysis of the BCIRG 005 study. Breast Cancer Res Treat 2005; 94, (Supple; abstr 1069)
   Web of Science ®Google Scholar
• Nabholtz J. M., Cantin J., Chang J., et al. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial. Clin Breast Cancer Oct, 2002; 3(4)268–275
   PubMedGoogle Scholar
• Martin M., Lluch A., Seguí M. A., et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol Aug, 2006; 17(8)1205–1212
   PubMed Web of Science ®Google Scholar
• Gradishar W. J., Tjulandin S., Davidson N., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol Nov 1, 2005; 23(31)7794–7803
   PubMed Web of Science ®Google Scholar
• Robert N., Ambro S., Krekow L., et al. Pilot study of dose dense doxorubicin + cyclophosphamide followed by ABI-007 in patients with early stage breast cancer. Breast Cancer Res Treat 2005; 94, (Supple1;abstr 2073)
   Web of Science ®Google Scholar
• Low J. A., Wedam S. B., Lee J. J., et al. Phase II Clinical Trail of Ixabepilone (BMS-247550), an Epothilone B Analog, in Metastatic and Locally Advanced Breast Cancer. J Clin Oncol April, 2005; 23(12)2726–2734
   PubMed Web of Science ®Google Scholar
• Thomas E., Gomez H., Li R., et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25: 5210–5217
   PubMed Web of Science ®Google Scholar
• Cardoso F., de Azambuja E., Lago L. D. Current perspectives of epothilones in breast cancer. Eur J Cancer Jan 4, 2008
   Web of Science ®Google Scholar
• Jones S., Holmes F., O'Shaughnessy J., Blum J., et al. Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older. Breast Cancer Res Treat 2007; 106, (Supple;abstr 12)
   PubMed Web of Science ®Google Scholar
• Hasegawa S., Miyoshi Y., Egawa C., et al. Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 2003; 9(8)2992–2997
   PubMed Web of Science ®Google Scholar
• Paradiso A., Mangia A., Chiriatti A., et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol 2005; 16(Suppl 4)iv14–iv9
   PubMedGoogle Scholar
• Seve P., Reiman T., Lai R., et al. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol 2007; 60(1)27–34
   PubMed Web of Science ®Google Scholar
• Rouzier R., Rajan R., Wagner P., et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 2005; 102(23)8315–8320
   PubMed Web of Science ®Google Scholar
• Andre F., Hatzis C., Anderson K., et al. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 2007; 13(7)2061–2067
   PubMed Web of Science ®Google Scholar
• Barlow S. B., Gonzalez-Garay M. L., Cabral F. Paclitaxel-dependent mutants have severely reduced microtubule assembly and reduced tubulin synthesis. J Cell Sci 2002; 115: 3469–3478, (Pt 17)
   PubMed Web of Science ®Google Scholar
• Bernard-Marty C., Treilleux I., Dumontet C., et al. Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clin. Breast Cancer 2002; 3(5)341–345
   PubMedGoogle Scholar
• Salvatorelli E., Menna P., Cascegna S., et al. Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies. J. Pharmacol Exp Ther Jul, 2006; 318(1)424–433, Epub 2006 Apr 13
   PubMed Web of Science ®Google Scholar
• Slamon D. J., Mackey J., Robert N., et al. Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease. Proceedings of the 30th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, 2007, Abstract 13
   Google Scholar
• Henry N. L., Hayes D. F. Use of gene-expression profiling to recommend adjuvant chemotherapy for breast cancer. Oncol. Oct, 2007; 21(11)1301–1309
   Google Scholar
• Tang S. Molecular predictive markers of tubulin-targeting agents. Clinical Breast Cancer 2008; 8(suppl.)79–84
   Google Scholar